The clinical documentation outlines the medical presentation of Castle, a 12.1-year-old male neutered Corgi mix weighing thirty-five pounds. He presents with multiple splenic masses, initially identified via abdominal ultrasonography, which have subsequently demonstrated progressive enlargement upon serial monitoring. Crucially, the diagnostic imaging indicates that these masses are currently intact. There is no sonographic evidence of active hemoperitoneum resulting from capsular rupture, nor is there gross evidence of macroscopic pulmonary metastasis on the three-view thoracic radiographs. Because Castle's masses are incidentally identified and non-ruptured, the statistical probability shifts dramatically in favor of benign pathology, with up to 70.5% to 93.9% of these lesions representing benign entities such as splenic hematomas or nodular lymphoid hyperplasia. However, because advanced imaging cannot reliably or definitively differentiate between benign and malignant splenic masses, total splenectomy followed by exhaustive histopathological sectioning is the only definitive diagnostic modality available. The surgical estimate generated by Bargersville Veterinary Hospital & Wellness Center projects a total financial scope ranging from $1,773.81 to $2,012.71. Prior to surgery, establishing an explicit emergency contingency for Dog Erythrocyte Antigen (DEA) 1.1 typed blood product availability is paramount to prevent acute, life-threatening hemolytic reactions. Furthermore, the pre-operative assessment should ideally incorporate the measurement of cardiac biomarkers, specifically cardiac troponin I (cTnI), to identify occult cardiac hemangiosarcoma and provide vital prognostic information regarding baseline myocardial health. During the planned laparotomy, the performance of a concurrent prophylactic right-sided incisional gastropexy is a highly rational, minimally morbid surgical adjunct. Dogs with a history of splenectomy possess an odds ratio of 5.3 for developing subsequent Gastric Dilatation-Volvulus (GDV), and a gastropexy virtually eliminates the mechanical possibility of fatal gastric volvulus. In the immediate post-operative phase, continuous electrocardiographic monitoring is an absolute requirement to rapidly identify potentially lethal ventricular arrhythmias, which occur in up to fifty percent of patients within the first twelve to seventy-two hours. Additionally, prophylactic management of the severe hypercoagulable state and reactive thrombocytosis utilizing the antiplatelet agent clopidogrel has emerged as a promising standard of care to mitigate thromboembolic complications. A uniquely complex element of Castle's specific post-operative management involves a highly critical pharmacological conflict. He is currently receiving Librela (bedinvetmab) for osteoarthritis pain management, while the surgical estimate includes the NSAID Carprovet (carprofen) for post-operative analgesia. The profound inhibition of nerve growth factor via bedinvetmab combined synergistically with an NSAID has been directly linked to adverse events characterized as rapidly progressive osteoarthritis; therefore, post-operative mobility restrictions must be strictly and flawlessly enforced. Ultimately, if histopathology reveals a benign entity, the splenectomy is considered entirely curative. Conversely, a diagnosis of hemangiosarcoma would necessitate a rapid transition to adjuvant therapies such as Doxorubicin, metronomic chemotherapy, or immunomodulation with I'm-Yunity to meaningfully extend his survival. SEO Tags: Veterinary Oncology, Canine Splenic Mass, Corgi Health, Hemangiosarcoma, Splenectomy Risks, Bedinvetmab and NSAIDs, Canine Post-Operative Care, Gastric Dilatation-Volvulus Prophylaxis, Veterinary Surgery, I'm-Yunity, Clopidogrel Sources Cited: Castle's Splenic Mass Care Plan: Clinical and Oncological Management Strategy for Canine Splenic Neoplasia. Curated and Created by Kenneth Henseler using Gemini & Notebook
